x
ServiziMenu principaleHome
You are here: Home > Events > Past events > 2011 > 2nd Interdisciplinary Conference - Prostate Cancer: Predictive Models for Decision Making
Print

2nd Interdisciplinary Conference - Prostate Cancer: Predictive Models for Decision Making

Not eligible for ESCO credits

07.04.2011  -  09.04.2011

New York

CONFERENCE

Prostate cancer

Description

Chair: Peter T. Scardino, MD, US 
Co-Chair: Riccardo Valdagni, MD, PhD, IT
Honorary Chair: Louis J. Denis, MD, BE

Scientific Coordinator: Karim Touijer, MD, US

 

 

 

TOPICS
Predictive models in prostate cancer with respect to:
- construction, accuracy and data management
- genomic and bio-molecular sciences
- histopathology and systems pathology
- risk of cancer on biopsy
- indolent and low risk tumor
- focal cancer
- pathologic stage and grade
- active surveillance
- surgery and related toxicity
- radiotherapy and related toxicity (external radiotherapy and brachytherapy)
- radiotherapy combined with hormonal therapy and related toxicity
- recurrent disease
- metastatic disease
- toxicity after androgen deprivation
- toxicity after chemotherapy
- clinical trial design and medical decision making
- future trends in the research

 

EDUCATIONAL OBJECTIVES
- To define the state of the art of predictive modeling in prostate cancer
- To evaluate the application of predictive models in daily clinical practice
- To determine the future research trends within the oncologic community


TARGET AUDIENCE
Urologists, radiation oncologists, medical physicists, medical oncologists, pathologists, biostatisticians and investigators in outcomes research and genomics.



 

A CME Conference jointly sponsored by
ESO and Memorial Sloan-Kettering Cancer Center 

 

General information

OFFICE OF CME
Memorial Sloan-Kettering Cancer Center, New York (US)
Telephone: (646) 227-2025
Facsimile:  (212) 557-0773
E-mail:
brodheap@mskcc.org
Website: www.mskcc.org/cme



PROSTATE CANCER PROGRAMME

European School of Oncology
Milan (Italy)
Telephone: +39 02 85464527
Facsimile: +39 02 8546451
E-mail:
prostate@eso.net
Website: www.eso.net


CONFERENCE LOCATION
Memorial Sloan-Kettering Cancer Center
Rockefeller Research Laboratories Auditorium
430 East 67th Street
Between First and York Avenues
New York, NY 10065 (USA)


EVALUATION
A course evaluation form will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.


ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Memorial Sloan-Kettering Cancer Center and the European School of Oncology. Memorial Sloan-Kettering Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.
European School of Oncology will apply for ACOE accreditation.


AMA CME CREDIT DESIGNATION STATEMENT
Memorial Sloan-Kettering Cancer Center designates this educational activity for a maximum of 18.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


COMMERCIAL SUPPORT
No commercial support has been provided for this CME activity. Memorial Sloan-Kettering Cancer Center (MSKCC) does not accept commercial support for its CME Program.


FACULTY DISCLOSURE
Memorial Sloan-Kettering Cancer Center (MSKCC) relies upon faculty participants in its CME Program to provide educational information that is objective and as free from bias as possible. In accordance with nationally accepted guidelines, faculty members are asked to indicate any commercial relationship that might be perceived as a real or apparent conflict of interest.


CERTIFICATES
All participants will be issued  with an ESO–MSKCC certificate of attendance at the end of the Conference.


OFFICIAL LANGUAGE
The official language of the conference is English. No simultaneous translation will be provided.


BADGE
Your name badge is the only official evidence of registration and should be worn at all times during the Conference. 


INSURANCE
The organizers bear no responsibility for untoward events in connection between with, before, during and after the conference. Participants are strongly advised to take their own personal and travel insurance coverage.


IMPORTANT DEADLINES
Early registration: before MARCH 25, 2011
Registration: MARCH 25 through APRIL 7, 2011
Cancellation deadline: MARCH 25, 2011
Replacement deadline: MARCH 25, 2011



 

 

 

Faculty list

 

PROVISIONAL FACULTY
Gerald L. Andriole, Div. Urology, Washington University School of Medicine in St. Louis, Barnes Jewish Hospital, St. Louis, US
Peter Bach, Div. Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, US
Chris Bangma, Head, Dept. Urology, Erasmus Medical Centre, Rotterdam, NL
Ethan Basch, Div. Medicine, Memorial Sloan Kettering Cancer Center, New York, US
Joaquim Bellmunt, Section Chief, Solid Tumor Oncology (GU & GI) Medical Oncology Service, Hospital del Mar, Barcelona, ES
Anders Bjartell, Professor in Clinical Urology, Dept. Urology, Malmö and Lund University Hospitals, Lund University, Malmö, SE
Peter R. Carroll, Director, Clinical Services and Strategic Planning, Helen Diller Family Comprehensive Cancer Center, University of California,
San Francisco, US
Carlos Cordon Cardo, Vice-Chair and Professor of Pathology, Columbia University, New York, US
Brett W. Cox, Brachytherapy Service, Memorial Sloan Kettering Cancer Center, New York, US
David Dearnaley, Professor of Uro-Oncology, Dept. Radiotherapy, Institute of Cancer Research, London, UK
Louis Denis, Director, Oncology Centre Antwerp (OCA), Antwerp, BE
James A. Eastham, Chief, Urology Service and Florence and Theodore Baumritter/Enid Ancell Chair, Urologic Oncology,
Memorial Sloan Kettering Cancer Center, New York, US
Mark Emberton, Divisional Clinical Director, Cancer Services, University College Hospitals, and Clinical Director, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK
Jonathan I. Epstein, Professor, Departments of Pathology, Urology, & Oncology, The Reinhard Professor of Urologic Pathology, Johns Hopkins Medical Institutions, and Director, Surgical Pathology, Dept. Pathology, Johns Hopkins Hospital, Baltimore, US
Paul A. Fearn, NLM Informatics Research Fellow at University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, US
Roberto Gallina, Dept. Urology, Istituto Scientifico San Raffaele, Milan, IT
Christopher Foster, Professor of Cellular Pathology and Molecular Genetics, University of Liverpool, Liverpool, UK
Peter Hoskin, Professor and Honorary Consultant in Clinical Oncology, University College London, and Consultant in Clinical Oncology,
Mount Vernon Cancer Centre, Northwood, UK
Hedvig Hricak, Chair, Dept. Radiology, Memorial Sloan Kettering Cancer Center, New York, US
Maha Hussain, Associate Director for Clinical Research, Dept. Internal Medicine, University of Michigan Health System, Ann Arbor, US
Andrew Jackson, Dept. Medical Physics, Memorial Sloan Kettering Cancer Center, New York, US
Michael W. Kattan, Chair, Department Quantitative Health Sciences, Cleveland Clinic, Cleveland, US
Eric Klein, Chair, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, US
Laurence Klotz, Chief, Div. Urology, Sunnybrook Health Science Centre, Toronto, CA
Mark Litwin, Professor of Urology and Health Services, University of California, and Clark Urological Center, Ronald Reagan UCLA Medical Center, Los Angeles, US
Alvaro A. Martinez, Corporate Chairman, Radiation Oncology Dept., William Beaumont Hospitals, Royal Oak, US
Rodolfo Montironi, Institute of Pathological Anatomy and Histopathology, Marche Polytechnic University, United Hospitals, Le Torrette, IT
Francesco Montorsi, Head, Sexual Medicine Unit, Attending Urologist, Dept. Urology, Istituto Scientifico San Raffaele, Milan, IT
John P. Mulhall, Director, Male Sexual and Reproductive Medicine Program, Memorial Sloan Kettering Cancer Center, New York, US
Robert Nam, Clinical Epidemiology, Odette Cancer Research Program, Sunnybrook Health Science Centre, Toronto, CA
Simon Powell, Chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, US
Andrea Pusic, Div. Plastic Surgery, Memorial Sloan Kettering Cancer Center, New York, US
Farhang Rabbani, Associate Professor, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, US
Tiziana Rancati, Prostate Program, Scientific Director’s Office, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
Victor E. Reuter, Vice Chair, Dept. Pathology and Director, Immunohistochemistry Core Facility, Memorial Sloan Kettering Cancer Center, New York, US
Mack Roach III, Professor, Depts. Radiation Oncology & Urology, Chairman, Dept. Radiation Oncology, UCSF Comprehensive Cancer Center,
San Francisco, US
Fred Saad, Professor and Chief of Urology, Centre Hospitalier de l’Université de Montréal, Montréal, CA
Martin G. Sanda, Director, Prostate Care Center, Div. Urology, Beth Israel Deaconess Medical Center, Boston, US
Jaspreet S. Sandhu, Dept. Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, US
Charles L. Sawyers, Chair, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, US
Peter T. Scardino, Chief, Dept. Surgery, Memorial Sloan Kettering Cancer Center, New York, US
Howard I. Scher, Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, US
Matthew R. Smith, Associate Professor, Dept. Medicine, Harvard Medical School, Assistant in Medicine, Hematology/Oncology,
Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, Boston, US
Andrew Stephenson, Head, Urologic Oncology, Cleveland Clinic's Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, US
Cora N. Sternberg, Head, Dept. Medical Oncology, Ospedale San Camillo, Rome, IT
Steven Stone, V.P. of Cancer Genomics, Myriad Genetics Inc, Salt Lake City, US
Karim Touijer, Assistant Attending, Dept. Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, Assistant Professor of Urology,
Weill Medical College, Cornell University, New York, US
Riccardo Valdagni, Director, Prostate Program, Scientific Director’s Office, Director, Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
Hein Van Poppel, Chair, Dept. Urology, University Hospital Gasthuisberg, Katholieke Universiteit,  Leuven, BE
Andrew Vickers, Associate Attending Research Methodologist, Div. Health Outcomes, Dept. Epidemiology & Statistics, Memorial Sloan Kettering Cancer Center, New York, US
Anthony L. Zietman, Professor of Radiation Oncology, Dept. Radiation Oncology, Harvard Medical School, and Director, Radiation Oncology Residency Program, Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, Boston, US

Programme

April 7th

 8:00am

Opening and welcome
P.T. Scardino, US

  8:05am

Making predictions throughout history
R. Valdagni, IT     

SESSION 1: PREDICTIVE MODELS FROM BENCH TO BEDSIDE AND BACK TO BENCH
Chair: P.R. Carroll, US - R. Montironi, IT

  8:20am

Data management for predictive tools 
P.A. Fearn, US

 8:35am

Construction of predictive tools and measurements of their accuracy  
M.W. Kattan, US

 8:50am

Imaging and outcomes prediction   
H. Hricak, US

 9:05am

From cancer biomarkers to therapeutic targets 
C. Foster, UK

 9:20am

Gene copy number analysis as a prognostic tool
C.L. Sawyers, US
   9:50amCoffee break
 10:10amTraditional statistical methods for evaluating prediction models are uninformative:
towards a decision analytic approach  
A. Vickers, US
 10:25amCell cycle progression genes differentiate indolent from aggressive prostate cancer 
S. Stone, US    
 10:40amSystems pathology and outcome predictive models
C. Cordon Cardo, US 

 10:55am

Principles of biomarkers from discovery to qualification
H.I. Scher, US
PANEL DISCUSSION

 11:25am

DO MOLECULAR MARKERS IMPROVE PREDICTIVE MODELS?
Chair: P.R. Carroll, US - R. Montironi, IT
Panelists: C. Cordon Cardo, US - P.A. Fearn, US -C. Foster, UK - M.W. Kattan, US
C.L. Sawyers, US - H.I. Scher, US - S. Stone, US - A. Vickers, US  

 12:05am

Lunch
SESSION 2: PREDICTING DIAGNOSIS AND STAGE
Chair: A. Bjartel, SW - J.A. Eastham, US

 1:10pm

Predicting risk of cancer on biopsy
R. Nam, CA   

 1:30pm

Upgrading/Downgrading of prostate cancer from biopsy to radical prostatectomy: Incidence and predictive factors 
V.E. Reuter, US           

 1:50pm

Predicting grade  
J.I. Epstein, US                  
SESSION 3: PREDICTIVE MODELS IN LOW RISK PROSTATE CANCER”
Chair: A. Bjartel, SE - M. Emberton, US

 2:25pm

Predicting indolent and low risk prostate cancer
C. Bangma, NL

 2:45pm

Predicting focal cancer
M. Emberton, UK             

 3:05pm

Active surveillance: PSA kinetics and biomarkes
L. Klotz, CA
PANEL DISCUSSION  

 3:25pm

PREDICTIVE MODELS IN LOW RISK CANCER: LIMITATIONS AND FUTURE NEEDS
Chair: C. Bangma, NL - P.T. Scardino, US
Panelists: B.W. Cox, US - P.R. Carroll, US - M. Emberton, UK - L. Klotz, CA
A. Vickers, US - A.L. Zietman, US
 * Discussion will follow each lecture

 

April 8th

SESSION 4: MODELS TO PREDICT PROGNOSIS AFTER THERAPY IN LOCALIZED PROSTATE CANCER
Chair: S. Powell, US - H. Van Poppel, BE

  8:00am

Predicting clinical and biochemical endpoints before surgery    
K. Touijer, US  

  8:15am

Predicting clinical and biochemical endpoints after surgery     
A. Stephenson, US

8:30am

Predicting clinical and biochemical endpoints before external radiotherapy   
B.W. Cox, US

8:50am

Predicting clinical and biochemical endpoints before external radiotherapy combined with hormonal therapy
D. Dearnaley, UK

9:10am

Predicting clinical and biochemical endpoints before brachytherapy     
A.A. Martinez, US

PANEL DISCUSSION 

9:30am

WHAT ARE THE LIMITATIONS OF CURRENT PREDICTIVE MODELS
Chair: E. Kein, US - F. Montorsi, IT
Panelists: A. Bjartell, SE - D. Dearnaley, UK - M.W. Kattan, US - M. Roach III, US
F. Saad, CA - A. Stephenson, US - C.N. Sternberg, IT

10:00am

Coffee break
SESSION 5: MODELS TO PREDICT PROGNOSIS IN ADVANCED DISEASE
Chair: J. Bellmunt, ES - H.I. Scher, US

 10:15am

Predicting life expectancy       
A. Vickers, US

 10:40am

Predicting response to hormonal therapy and survival in men with metastatic disease
M.H. Hussain, US

 11:05am

Role of Circulating Tumor Cells in predicting survival in men with castration resistant disease
C.N. Sternberg, IT
PANEL  DISCUSSION  

 11:30am

DO WE NEED BETTER PREDICTIVE MODELS IN ADVANCED PROSTATE CANCER?
Chair: M.R. Smith, US - C.N. Sternberg, IT
Panelists: J. Bellmunt, ES - J. Eastham, US - P. Hoskin, UK - M.H. Hussain, US
M.W. Kattan, US - M. Roach III, US - H.I. Scher, US

 12:10am

Lunch
SESSION 6: QUALITY OF LIFE OUTCOME MEASUREMENT
Chair: D. Dearnaley, UK - E. Klein, US

 1:10pm

Documenting outcomes with patient reported questionnaires  
M. Litwin, US 

 1:30pm

Measuring side effects with validated quality of life instruments  
M.G. Sanda, US

 1:50pm

Quality of life instruments and their role in cancer care  
A. Pusic, US
PANEL DISCUSSION

 2:10pm

ADVANTAGES AND LIMITATIONS OF CURRENT QUALITY OF LIFE INSTRUMENTS
Chairs: L. Klotz, CA - F. Montorsi, IT
Panelists: E. Basch, US - P. Hoskin, UK - E. Klein, US - M. Litwin, US
A. Pusic, US - M.G. Sanda, US - A. Vickers, US

 2:40pm

Coffee break
 THREE BREAKOUT SESSIONS
SESSION 7: MODELS TO PREDICT THERAPY INDUCED TOXICITIES
 UROLOGY ROOM
Chair:
J.A. Eastham, US - J.P. Mulhall, US  

 3:00pm

Should surgeon specific factors be incorporated in prediction modeling?
A. Vickers, US

 3:25pm

Predicting toxicity after surgery: incontinence  
J.S. Sandhu, US           

 3:50pm

Predicting toxicity after surgery: erectile dysfunction   
R. Gallina, IT 

 4:15pm

Predicting toxicity after surgery: morbidity and complications
F. Rabbani, US          

 4:40pm

Surgery group discussion
How to design the next generation of predictive models in Urology?

 5:00pm

End of the Session       
 RADIATION ONCOLOGY ROOM
Chair:
A. Jackson, US - A.L. Zietman, US

 3:00pm

How the radiation oncologist and the radiation technique affect outcome   
P. Hoskin, UK

 3:20pm

Predicting toxicity after external radiotherapy: sexual and urinary dysfunction
M. Roach III, US 

 3:40pm

Predicting toxicity after external radiotherapy: gastro-intestinal dysfunction
R. Valdagni, IT

 4:00pm

Predicting toxicity after brachytherapy
A.A. Martinez, US

 4:20pm

Predicting radio-induced toxicity: the challenge of moving from qualitative events to quantitative scoring
T. Rancati, IT

 4:40pm

Volume effects and dose responses in rectal complications of external beam radiotherapy 
J. Jackson, US

 5:00pm

Radiation Oncology group discussion
How to design the next generation of predictive models in radiation oncology?
       

 5:20pm

End of the Session                         
 MEDICAL ONCOLOGY ROOM 
Chair: M.H. Hussain, US - H.I. Scher, US

 3:00pm

Predicting toxicity after androgen deprivation: cardiovascular events    
M.R. Smith, US

 3:25pm

Predicting toxicity after androgen deprivation: skeletal adverse events   
F. Saad, US

 3:50pm

Role of predictive biomarkers as a measure of individualized medicine  
M.H. Hussain, US

 4:15pm

Medical Oncology group discussion
How to design the next generation of predictive models for advanced disease?

 5:00pm

End of the Session
 * Discussion will follow each lecture

 

April 9th

HIGHLIGHTS OF THE BREAKOUT SESSIONS

  8:30am

Urology room          
K. Toujier, US   

  8:45am

Radiation Oncology room         
B.W. Cox, US    

9:00am

Medical Oncology room
F. Saad, CA
 

Summary
M.R. Smith, US

SESSION 8: POINT, COUNTERPOINT”
Chair: L. Denis, BE - P.T. Scardino, US

9:30am

DEBATE 1: "DO I NEED A NOMOGRAM TO MAKE GOOD DECISIONS?"
The answer is no
H. Van Poppel, BE
The answer is yes
M.W. Kattan, US

10:20am

PANEL DISCUSSION
Chair: E. Klein, US - H.I. Scher, US
Panelists: C. Cordon Cardo, US - P. Hoskin, UK  - R. Montironi, IT - V.E. Reuter, US
S. Stone, US - A. Vickers, US
 10:30amCoffee break 

10:50am

DEBATE 2: "CATEGORICAL STAGING VERSUS CONTINUOUS PREDICTION: HOW CAN WE INTEGRATE PREDICTIVE MODELS INTO THE STAGING SYSTEMS?" 
Categorical staging works!
P.R. Carroll, US  
Categorical staging vs prediction models: what is the evidence?
A. Vickers, US

 11:20amPANEL DISCUSSION
Chair: K. Touijer, US - H. Van Poppel, BE
Panelists: P. Bach, US - P.R. Carroll, US - D. Dearnaley, UK, - M.W. Kattan, US
F. Montorsi, IT - M. Roach III, US - M.R. Smith, US 
 11:50amDEBATE 3: "CLINICAL TRIALS DESIGN"
Predictive models are a better way to stratify patients for clinical trials
J.A. Eastham, US  
Standard stratification is adequate for clinical trials
G.L. Andriole, US

 12:20am

PANEL DISCUSSION
Chair: P. Hoskin, UK - C.N. Sternberg, IT
Panelists: A. Bjartell, SE - D. Dearnaley, UK - M.H. Hussain, US - M. Roach III, US
M.R. Smith, US - A. Vickers, US

 12:50am

Closing Remarks
 * Discussion will follow each lecture